145 related articles for article (PubMed ID: 36822945)
1. Micro-elimination of hepatitis C virus infection in the rural and remote areas of Taiwan - A multi-center collaborative care model.
Lo CC; Lei WY; Huang YC; Hwang JJ; Lo CY; Lin CH; Cheng HS; Liao YT; Liang PC; Chiou MJ; Bair MJ; Dai CY; Yu ML
J Microbiol Immunol Infect; 2023 Aug; 56(4):680-687. PubMed ID: 36822945
[TBL] [Abstract][Full Text] [Related]
2. Liver Disease Screening and Hepatitis C Virus Elimination in Taiwan Rural Indigenous Townships: Village-By-Village Screening and Linking to Outreach Hepatology Care.
Tien HM; Cheng TC; Lien HC; Yang KF; Shy CG; Chen YL; Hsu NT; Lu SN; Wang JH
Int J Environ Res Public Health; 2022 Mar; 19(6):. PubMed ID: 35328957
[TBL] [Abstract][Full Text] [Related]
3. Collaborative Referral Model for Hepatitis C Screening and Treatment in a Remote Mountainous Region of Taiwan during the COVID-19 Pandemic.
Tai CM; Bair MJ; Chen TH; Tseng CH; Chen CC; Lam H; Yu ML
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112808
[TBL] [Abstract][Full Text] [Related]
4. Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison.
Chen CT; Lu MY; Hsieh MH; Tsai PC; Hsieh TY; Yeh ML; Huang CI; Tsai YS; Ko YM; Lin CC; Chen KY; Wei YJ; Hsu PY; Hsu CT; Jang TY; Liu TW; Liang PC; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Shih YL; Yu ML
World J Gastroenterol; 2022 Jan; 28(2):263-274. PubMed ID: 35110949
[TBL] [Abstract][Full Text] [Related]
5. A people-centered decentralized outreach model toward HCV micro-elimination in hyperendemic areas: COMPACT study in SARS Co-V2 pandemic.
Huang CI; Liang PC; Wei YJ; Tsai PC; Hsu PY; Hsieh MY; Liu TW; Lin YH; Hsieh MH; Jang TY; Wang CW; Yang JF; Yeh ML; Huang CF; Dai CY; Chuang WL; Huang JF; Yu ML
J Microbiol Immunol Infect; 2023 Jun; 56(3):586-597. PubMed ID: 37188573
[TBL] [Abstract][Full Text] [Related]
6. Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study).
Huang JF; Hsieh MY; Wei YJ; Hung JY; Huang HT; Huang CI; Yeh ML; Huang CF; Jang TY; Hsu PY; Liang PC; Dai CY; Lin ZY; Yu ML; Chuang WL
Hepatol Int; 2022 Feb; 16(1):59-67. PubMed ID: 34850326
[TBL] [Abstract][Full Text] [Related]
7. Hepatocellular carcinoma after a sustained virological response by direct-acting antivirals harbors TP53 inactivation.
Imamura T; Okamura Y; Ohshima K; Uesaka K; Sugiura T; Ito T; Yamamoto Y; Ashida R; Ohgi K; Otsuka S; Ohnami S; Nagashima T; Hatakeyama K; Kakuda Y; Sugino T; Urakami K; Akiyama Y; Yamaguchi K
Cancer Med; 2022 Apr; 11(8):1769-1786. PubMed ID: 35174643
[TBL] [Abstract][Full Text] [Related]
8. Recently acquired hepatitis C virus infection among people living with human immunodeficiency virus at a university hospital in Taiwan.
Huang MH; Sun HY; Ho SY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Su LH; Liu WC; Su YC; Hung CC
World J Gastroenterol; 2021 Oct; 27(37):6277-6289. PubMed ID: 34712032
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Chen CY; Huang CF; Cheng PN; Tseng KC; Lo CC; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Kao JH; Chuang WL; Lin HC; Yu ML
Liver Int; 2021 Jun; 41(6):1265-1277. PubMed ID: 33655714
[TBL] [Abstract][Full Text] [Related]
10. Elimination of Hepatitis C Virus in a Dialysis Population: A Collaborative Care Model in Taiwan.
Hu TH; Su WW; Yang CC; Yang CC; Kuo WH; Chen YY; Yeh YH; Chen SS; Tsao YY; Chen KM; Yan SL; Lai JH; Yao CD; Lim CH; Jen HH; Yeh YP; Chen SL; Chen HH; Chen SC;
Am J Kidney Dis; 2021 Oct; 78(4):511-519.e1. PubMed ID: 33940114
[TBL] [Abstract][Full Text] [Related]
11. Liver-related complications before and after successful treatment of chronic hepatitis C virus infection in people with inherited bleeding disorders.
Isfordink CJ; van Erpecum KJ; Fischer K; van der Valk PR; van Vulpen LFD; Schutgens REG; Arends JE; Mauser-Bunschoten EP
Haemophilia; 2023 Jan; 29(1):106-114. PubMed ID: 36184751
[TBL] [Abstract][Full Text] [Related]
12. Reverse inflammaging: Long-term effects of HCV cure on biological age.
Oltmanns C; Liu Z; Mischke J; Tauwaldt J; Mekonnen YA; Urbanek-Quaing M; Debarry J; Maasoumy B; Wedemeyer H; Kraft ARM; Xu CJ; Cornberg M
J Hepatol; 2023 Jan; 78(1):90-98. PubMed ID: 36152762
[TBL] [Abstract][Full Text] [Related]
13. The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-infected patients.
Wong YJ; Thurairajah PH; Kumar R; Fock KM; Law NM; Chong SY; Manejero FG; Ang TL; Teo EK; Tan J
Clin Mol Hepatol; 2021 Jul; 27(3):474-485. PubMed ID: 33601868
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
15. Liver Health Literacy and Health Status Among Adults With Hepatitis C: Implications for the Nursing Profession as Part of the 2030 Global Elimination Goal.
Lin YC; Chiu WN; Chang TS; Huang TJ; Chen MY
J Nurs Scholarsh; 2020 Mar; 52(2):128-135. PubMed ID: 31750620
[TBL] [Abstract][Full Text] [Related]
16. Can Telementoring Reduce Urban-Rural Disparities in Utilization of Direct-Acting Antiviral Agents?
Du P; Wang X; Kong L; Jung J
Telemed J E Health; 2021 May; 27(5):488-494. PubMed ID: 32882154
[No Abstract] [Full Text] [Related]
17. Collaborative Referral Model to Achieve Hepatitis C Micro-Elimination in Methadone Maintenance Treatment Patients during the COVID-19 Pandemic.
Tai CM; Huang CK; Changchien TC; Lin PC; Wang DW; Chang TT; Chan HW; Chen TH; Tseng CH; Chen CC; Tsai CT; Sie YT; Yen YC; Yu ML
Viruses; 2022 Jul; 14(8):. PubMed ID: 35893702
[TBL] [Abstract][Full Text] [Related]
18. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations.
Yu ML; Chen PJ; Dai CY; Hu TH; Huang CF; Huang YH; Hung CH; Lin CY; Liu CH; Liu CJ; Peng CY; Lin HC; Kao JH; Chuang WL
J Formos Med Assoc; 2020 Jul; 119(7):1135-1157. PubMed ID: 32354689
[TBL] [Abstract][Full Text] [Related]
19. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
20. Treatment of chronic hepatitis C in Asia: when East meets West.
Yu ML; Chuang WL
J Gastroenterol Hepatol; 2009 Mar; 24(3):336-45. PubMed ID: 19335784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
